Videos
Press Releases
22 Sep 2022
EORTC Quality of Life Group celebrating 40 years
31 Aug 2022
EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Latest Newsletters
News
17 Sep 2024
Breast Cancer Group,Genito-Urinary Cancers Group,Head and Neck Cancer Group,Lung Cancer Group,Melanoma Group,News
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
16 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
10 Sep 2024
EORTC’s presence at ESMO 2024
9 Jul 2024
Meet the new EORTC Board
17 Jun 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
24 May 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
20 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
8 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
29 Apr 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Feb 2024
EORTC: Advancing research and treatment for rare cancers
